Pharmaceutical Particle Engineering via Spray Drying
- First Online:
- Cite this article as:
- Vehring, R. Pharm Res (2008) 25: 999. doi:10.1007/s11095-007-9475-1
- 11k Downloads
This review covers recent developments in the area of particle engineering via spray drying. The last decade has seen a shift from empirical formulation efforts to an engineering approach based on a better understanding of particle formation in the spray drying process. Microparticles with nanoscale substructures can now be designed and their functionality has contributed significantly to stability and efficacy of the particulate dosage form. The review provides concepts and a theoretical framework for particle design calculations. It reviews experimental research into parameters that influence particle formation. A classification based on dimensionless numbers is presented that can be used to estimate how excipient properties in combination with process parameters influence the morphology of the engineered particles. A wide range of pharmaceutical application examples—low density particles, composite particles, microencapsulation, and glass stabilization—is discussed, with specific emphasis on the underlying particle formation mechanisms and design concepts.
Key wordsdispersibilitymicroencapsulationparticle formationrespiratory drug deliverystabilization
Many solid dosage forms in the pharmaceutical and biotech industries are based on microparticles. Dry powders are inhaled as aerosols into the lung, delivered to the nose, filled into capsules, or pressed into tablets for oral applications, or even delivered transdermally. In the past, microparticles were often viewed simply as carriers, usually micronized dry material, without sophisticated attributes. The primary functions of the micronization and drying processes were to achieve a suitable particle size and remove most of the solvent. This perspective has changed as novel drug delivery strategies were developed. More advanced therapeutic approaches have created complex requirements for dosage forms that can only be met by particles that are designed for a range of functions such as stabilization of the active, transport and targeting of the dose, or release modulation. The particle is no longer seen as a passive carrier, but rather as an essential part of the drug delivery system.
Particle Engineering is a young discipline that combines elements of microbiology, chemistry, formulation science, colloid and interface science, heat and mass transfer, solid state physics, aerosol and powder science, and nanotechnology. It provides the theoretical framework for a rational design of structured microparticles. Particle engineering requires a deeper understanding of particle formation processes. Complex structured microparticles are difficult to design using an empirical approach alone because of the many process and formulation variables that need to be tuned correctly to achieve the desired result.
Efforts to understand and control particle formation processes were intensified in the last decade, coinciding with the development of pulmonary therapeutics that were traditionally given by injection (1–3). The pulmonary route was found to be viable for systemic delivery of proteins and peptides (4–6), in particular insulin (7–18), triggering the development of diverse administration systems and particle engineering strategies (19–28).
Microparticles can be manufactured by many different processing methods. This review focuses exclusively on spray drying (29–35), with an emphasis on the literature of the last five years. Wet chemistry and phase separation processes and alternative drying processes such as spray freeze drying, or supercritical fluid technologies, have also been used widely for particle engineering purposes and have been reviewed elsewhere (36–41).
DEFINITIONS AND THEORY
The purpose of this section is to clarify the terminology needed for a discussion of particle engineering. It will also provide equations that can be used to describe particle properties and the particle formation process. A rigorous treatment of the physics and chemistry that form the foundation of particle engineering is beyond the scope of this review and the reader is referred to several textbooks (29,42–45) that cover this material in more detail. Rather, this section will focus on working equations that can be used to link material properties and process parameters to particle, aerosol, or powder properties and the resultant product attributes. An engineering approach is used, relying on dimensionless numbers, and approximate expressions are presented where the exact equations are cumbersome to use.
Terminology of Structured Microparticles
Particle morphology can be described in terms of particle size, shape, internal structure, and surface properties. The terminology used in the literature to describe structured microparticles is inconsistent; this review suggests the following:
Particles can also have the cellular structure of solid foams, shown schematically in Fig. 1c and e. In contrast to voids, which are simply gas-filled space, cells are defined by a surrounding layer such as a membrane. Foam physics terminology can be used to describe the characteristics of the cellular material: in the case of a closed cell structure (Fig. 1c) the membranes of adjoining cells remain mostly intact, while in an open cell structure (Fig. 1e) the membranes have ruptured, leaving a network of struts behind which are called Plateau borders. The cells can be described as the dispersed phase and the interstitial matter between the cells as the continuous phase. Colloid science terminology is also applicable to particles that were created from suspensions of solids. Fig. 1d and f show schematic examples where the dispersed phase consists of smaller solid particles, typically nanoparticles. Two cases of particles are shown; a carrier particle where a significant fraction of the particle mass is in the continuous phase with few embedded smaller particles, and the opposite case of a particle with most of the mass in the dispersed phase. In the latter case the nanoparticles have formed a composite shell. A large number of small, homogenously dispersed, solid nanoparticles give the particle the nature of a sol. Embedded nanoparticles or liquid nanodroplets may have a coat or membrane at the solid–solid or liquid–solid phase interface. The latter case, a gel particle, is often called a dry emulsion in the literature (46–48). Fig. 1g shows a particle with internal composition gradients which has an irregular surface forming external voids. The term irregular is used for particles whose primary form deviates significantly from that of a perfect sphere, such as indented or wrinkled particles. Irregular particles may still be spherical, i.e. their aspect ratio may be close to one.
With few exceptions, spray dried particles are spherical and their size can be described by their geometric diameter. This is an important parameter which influences the forces particles experience in fluid flows and the packing of particles when they form a powder. The geometric diameter is also often used as a reference, because it is in principle directly accessible by ultramicroscopic techniques.
However, the measurement of geometric diameters by image analysis is not without difficulties. One is rarely interested in the size of just a single particle, but rather the size distribution of all particles in a product. In the context of pharmaceutical applications the mass fraction of a particulate dosage form in a certain particle size interval is often sought. This information can be obtained by image analysis of a sample of the dose, but care has to be taken to ensure that a representative, statistically relevant sample is analyzed. Usually, this can only be accomplished with the help of automated microscopy and image analysis (49). Image analysis techniques generate count-based distributions that have to be converted to a mass-based distribution, e.g. with the help of the Hatch Choate equations (44).
The geometric diameter of particles that are not perfect spheres depends on their orientation. In this case an average geometric diameter can be substituted, e.g. by averaging Feret’s horizontal and vertical diameters (50). If this is carried out on a large number of particles that are randomly oriented, the reported geometrical diameter is the orientation averaged Feret’s diameter.
Other common particle sizing techniques do not measure the geometric diameter directly, but rather derive it from the behavior of the particles in response to the probe used in the analysis. The reported diameters are often confused with geometric diameters, but are in fact equivalent diameters specific to the analytical technique (49). A common example is an optical-equivalent diameter where particles are probed by a light source. Their scattering or absorption behavior is compared to that of a reference geometry, usually a homogeneous sphere. The geometric diameter of the reference sphere is only representative of the diameter of the sample particle if the optical properties of the sample are close to that of the reference. For structured or irregularly shaped particles this is often not the case, as can easily be recognized considering the variety of particle types shown in Fig. 1. The optical particle size for these particles is in reality a function of their geometric diameter and their secondary morphological features (51,52). Equivalent particle diameters based on other properties or behavior such as electrical mobility, diffusion, sedimentation, surface or volume to surface ratio are used frequently and are described in the literature (49,53).
Equation 1 is a simplified description, valid for spheres in the continuum regime. Treatment and corrections for non-sphericity and transition regime flow can be found in the aerosol science literature (44,49,54). The particle density, ρP, in this equation should not be mistaken for the true density of the dried material. The particle density is the mass of the particle divided by the volume of a sphere of diameter dg and can be significantly lower than the true density, because it includes internal and external voids.
Atomizer performance directly influences the particle size of the dried particles. Four different types of atomizers are used for the majority of industrial spray drying applications; rotary atomizers, pressure nozzles, two-fluid nozzles (29,56), and ultrasonic atomizers (57,58). Typical droplet mass median diameters in pharmaceutical spray dryers range from less than 10 μm for pulmonary applications to upwards of 100 μm, which translates to a typical dry particle diameter range of 0.5 to 50 μm. Atomizer performance as a function of solution properties and operating conditions has been described elsewhere (29).
Distribution of Components in Spray Dried Particles
The key to successful particle engineering is understanding and controlling the mechanisms that determine the radial distribution of components during the drying process. Several different driving forces that may be responsible for separation of components have been suggested. Surface activity may lead to preferential adsorption of components on the droplet surface, causing a diffusional flux toward the surface. On the other hand, as the evaporating droplet shrinks its receding droplet surface leads to increasing solute concentrations at the surface. This causes a diffusional flux away from the surface (59). The diffusional motion inside an evaporating droplet must be correctly described to predict the resulting radial distribution of the individual components.
The evaporation of a solution droplet in a spray dryer is a coupled heat and mass transport problem. The process is driven by the difference between the vapor pressure of the solvents and their partial pressure in the gas phase. The rate of evaporation is determined by the balance of energy required to vaporize the solvent and the energy transported to the surface of the droplet. Various numerical models have been presented and reviewed (60–62) that describe the evaporation of multicomponent droplets in detail. Here a simplified analytical treatment is summarized.
Feed solution concentration
Initial concentration, component i
Surface concentration, component i
Solubility, component i
Average concentration, component i
Specific heat capacity, solvent vapor
Surface enrichment, component i
Diffusion coefficient, liquid phase
Diffusion coefficient, gas phase
Initial density ratio
Equilibrium temperature, droplet
Drying gas temperature
Wet bulb temperature
Gas temperature far away from droplet
Mass fraction of solvent at surface
Mass fraction of solvent far from surface
Standard enthalpy change of vaporization
Reference density, 1 g/cm3
Drying gas density
Characteristic droplet drying time
Characteristic time to saturation
Characteristic time for precipitation
Characteristic time to true density
Once the droplet temperature is determined, the vapor pressure or mass fraction at the surface of the droplet can be found using an Antoine equation (50) or tabulated data. Finally, the evaporation rate follows according to Eq. 13, and the Peclet numbers and the characteristic times for the components can be calculated. Frequently, no data is available for the diffusion coefficients of the solutes, but an estimate based on the Stokes–Einstein equation is usually sufficient.
Several corrections, e.g. for droplet–droplet interactions or for convective flow around the drying droplets would need to be introduced to describe the actual situation in a spray dryer. Adequate models describing droplet evaporation in spray dryers have been developed in combustion research (67) and the food industry (68,69). Modeling of flow fields in spray dryers has been accomplished (34). The usefulness of the simple approach presented here lies in its potential to provide a quick overview of general trends for a particular particle design problem. It allows an assessment of the relative importance of various process parameters and material properties. This treatment cannot describe the processes that occur during the solidification of the particles, such as precipitation or buckling of shells (70), and it does not account for surface activity. However, it can approximate the radial distribution of all components prior to solidification. This may be predictive of the structure of the dry particle, as has been pointed out in an excellent study on the drying of milk powder (59). Hence, this model allows an estimate of which component is likely to act as a shell former.
A comprehensive theoretical description of particle formation during spray drying has not been published. The drying process of micro-droplets proceeds through non-equilibrium states where material properties are frequently unknown and experimentally difficult to access. Therefore, much of what is known about microparticle drying has been derived experimentally. It is worthwhile to review the experimental techniques that have been used to study droplet evaporation and particle formation. When interpreting the results of these studies it is important to consider the inherent limitations of the particular methods.
Various experimental techniques for the investigation of droplet drying and particle formation have been introduced. Studies using actual processing equipment are difficult to execute and interpret, because of the complexity of the two-phase flow in spray dryers, the difficulty of installing adequate analytical instrumentation into a development dryer, and the large number of processing and formulation variables. Consequently, most of the techniques study more or less simplified systems that are models of the actual situation in a dryer.
Arguably the most simplified system is a single droplet in quiescent gas. Various levitation techniques, using optical, acoustic, or electrodynamic forces can be used to freely levitate single microdroplets (71,72). Non-contact probing of the evaporating droplets allows measurement of evaporation rates with minimal interference. The shortcoming of the technique is in the time-scales that can be probed. It is difficult to introduce and levitate microdroplets in the experimental apparatus quickly enough to allow observation of a phenomenon with a characteristic time on the order of 10 ms. Most studies on freely levitated droplets have used either larger droplets or liquids with very low vapor pressure that evaporate so slowly that the initial droplet capture and stabilization becomes short compared to the time of the measurement. A second disadvantage of this method is that shrinking and solidifying droplets experience a significant change in properties such as refractive index, charge state, or sphericity. This can lead to difficulties in maintaining a stable levitation until the end of the evaporation process.
An interesting variant of single droplet levitation uses the Leidenfrost phenomenon to trap droplets on a concave hot plate (70,73). This technique was successfully used to study shell buckling during particle formation. A drawback of this approach is that the flow and temperature fields near the droplet are not similar to those of a free flowing droplet in a spray dryer.
The latter complication has been addressed by studying droplets suspended from thin filaments. This technique was used to observe the particle formation process of millimeter-sized droplets; particle density and morphology as a function of latent heat of crystallization, solubility, and drying rate were investigated (74). A recent study used a similar experimental set-up with an added capability to measure the surface adhesion of single, partially dry particles as a function of particle composition and moisture content (69). A refined filament suspension technique was applied to monitor the drying process of milk droplets (75–78). The morphology of dried particles was studied using suspended droplets for more than forty years (62,79–84), and much useful information has been derived from these studies. However, the use of a filament to suspend droplets has limitations. Heat and mass transfer can be affected by heat conduction between droplet and filament. The technique requires relatively large droplets, typically in the millimeter diameter range. This is problematic, because the processes involved in droplet drying scale differently with diameter. Droplet behavior observed on millimeter sized droplets may not be representative of microdroplets that are of interest in pharmaceutical applications.
Realistically sized droplets have often been studied in small scale spray dryers (55,85). These studies have shed light on many individual aspects of the drying process. The importance of the ratio between droplet evaporation rate and diffusional motion of the solutes was recognized and the concept of the Peclet number has been used to explain low density particle morphology (86). It was also found that feed solution concentration (87) and solubility of the excipients affect particle morphology (88–90). Several studies show that precipitation kinetics and crystallization play an important role and may be affected by evaporation rate (91,92). It has also been pointed out that drying temperature has a strong effect on particle morphology (93,94).
Some researchers have used a chain of monodisperse free falling droplets to study heat and mass transfer, drying, and particle formation processes (80,95–98). With this technique the effect of drying rates on particle formation and the formation of internal voids in particles have been studied. The droplet generator commonly used in this technique produces closely spaced droplets, which may lead to droplet–droplet interactions (99–101), because the evaporation process is determined by gas phase transport processes. Furthermore, the studies were still carried out on relatively large droplets with a diameter >170 μm (102).
Recently, an improved droplet chain technique has been introduced (50) that is based on a droplet-on-demand generator. In this technique the droplet distance is a free variable and can be chosen so that droplets do not measurably interact. It is also capable of generating droplets in the diameter range useful for respiratory delivery. Basic particle formation mechanisms have been derived with this technique, which are categorized in the next section.
Low Peclet number
The Peclet number is influenced by a combination of material properties of the solute and the solvent and processing parameters that determine the evaporation rate. Even small molecules with comparatively large diffusion coefficients can be forced into significant surface enrichment with sufficiently large evaporation rates.
Evidence for this can be found in hollow lactose particles that were dried in a bench-top spray dryer at relatively high inlet temperatures (88,104,105). The processing parameters reported by the authors suggest a Peclet number larger than 1, which is indicative of the particle formation mechanism described in the next section.
High Peclet Number
Typical examples that fall into the category of high Peclet number particle formation are proteins and polymers. There are numerous examples in the literature reporting hollow and wrinkled or dimpled morphologies for spray dried protein (50,92,106–110), peptide (111,112) or polymer particles (57,90,113–118). An extreme case is the drying of droplets that contain suspended material such as nanoparticles (86,119). Compared to the receding droplet surface the suspended material can be considered as immobile. The resulting surface accumulation and formation of a thin shell are intuitive in this case.
Changing Peclet Number
Many questions regarding the details of particle formation in spray drying remain unanswered. What is the role of surface activity in shell formation? Can shell deformation be controlled? Do microdroplets boil and inflate at high drying gas temperatures?
It has been pointed out many times that surface active molecules can replace other formulation components at the droplet surface and are detected in increased concentration at the surface of the dry particle (122–133). It was also shown that the addition of small amounts of surface active material can affect the particle morphology (108). Many of these studies have used Electron Spectroscopy for Chemical Analysis (ESCA) to analyze the surface composition of the dry particles. Because the penetration depth of ESCA is on the order of only 5 nm (134), it cannot be decided whether the predominant material on the surface identified by ESCA has formed a shell or has simply coated the particle. Other methods capable of probing the sub-surface composition, such as selective extraction of surface components or confocal microscopy, are being explored (135). Recently, it has been shown that the addition of a small amount of a surface active molecule, trileucine, improves the dispersibility of particles without changing the morphology of the particle (136). This indicates a coat on the surface affecting the cohesiveness of the particles. A larger amount of trileucine corresponding to a high initial saturation of 0.25 was necessary to change the morphology of the particle, which is in line with the formation mechanism shown in Fig. 5. The presence of an ordered surface layer may initiate or shorten the precipitation of the supersaturated solute and thus indirectly affect the particle morphology. However, it is not clear whether a surfactant with high solubility, dried at low Peclet numbers, is capable of forming a shell by a different mechanism than the ones described above. In summary, there is currently no consensus on the role of surface active material in particle formation (133).
After a shell has formed on an evaporating droplet, it is likely to be deformed by stress, due to pressure differences (73) and changes in material properties caused by desiccation or phase transformations. This period of the particle formation process determines whether a dry particle remains a hollow sphere, forms dimples, or folds on itself. Because the type of morphology affects important particle and powder properties such as cohesiveness or dispersibility (107,137,138), it is desirable to understand and control shell deformation mechanisms. Theoretical approaches have been presented that describe the buckling of shells composed of nanoparticles (70) and the elastic deformation of polymer crusts on sessile drops (139). However, there is currently no comprehensive theoretical model and few experimental studies (140) to describe the shell deformation process on evaporating droplets in general. Studies are complicated by a severe lack of material properties in non-equilibrium states and the inability of current experimental methods to probe the process on realistic time and size scales.
It has been reported in the food drying literature (82) that large particles dried at gas temperatures above the boiling point of the solvent may inflate after shell formation due to build-up of internal gas pressure, potentially causing shell rupture or “blow-holes” in the shells. The author is not aware of any studies that directly observe this mechanism on droplets with a diameter on the order of 10 μm. Fig. 4 contains examples of particles dried above and below the boiling temperature of the solvent. Notably, the type of morphology does not change abruptly but rather continues a gradual trend to lower density. The associated optical size measurements show no evidence of inflation after shell formation (50). It can be concluded that the hole visible in these particles is not a “blow-hole” but rather a “sink-hole” caused by the drying of the droplet interior. It is unclear whether surface layers on small droplets pose sufficient diffusional resistance to impede evaporation enough so that the droplet temperature increases beyond the boiling temperature of the solvent. Even if that was the case, it is unclear whether droplet lifetimes on the order of milliseconds allow enough time for bubble nucleation. In addressing this question the size of the droplets and the scale of the spray dryer have to be considered carefully. This issue points to an inherent complication in spray drying; scale-up is not straightforward and may have significant effects on the morphology of the particles.
Low density or hollow particles are advantageous for several applications, but specifically for pulmonary drug delivery where they improve dispersibility and delivery efficiency by lowering the aerodynamic diameter of the particles. Several particle design strategies have been developed to create voids in particles to lower the density. A hollow sphere can be created by using a shell forming excipient in combination with suitable processing conditions as described above. Irregular spherical particles may have external void space in folds or dimples. A corrugated surface further assists in dispersibility by minimizing contact areas. The design of such wrinkled particles is reviewed in the next section and creation of internal void space by alternative methods in the following paragraphs.
Internal and external void space can be created by process conditions and formulations that cause early separation of a soft surface layer, which folds to form a wrinkled morphology. Early shell formation can be forced by choosing a high initial saturation, a high Peclet number, or a combination of both for the shell former.
The prominent formulation system in this class is known under the label “Large Porous Particles.” The concept was introduced with polymer particles made by double- and single-emulsification solvent evaporation procedures followed by a freeze-drying step (141). Later the term “Large Porous Particles” became associated with particles that consist of dipalmitoylphosphatidylcholine (DPPC) in combination with albumin and saccharides spray dried from a sub-azeotropic ethanol–water co-solvent system (142–146).
DPPC has a very low aqueous solubility of 5 μg/ml or less (146) and its initial saturation can be adjusted by the ethanol water ratio. During the evaporation the DPPC saturation increases faster than the saturation of hydrophilic formulation components due to the preferential evaporation of ethanol and the associated change in the co-solvent ratio with time. The diffusion coefficient of DPPC is also low, in particular when it assembles into organized lipid structures. These properties point to a very early shell formation, which can be achieved on a comparatively large droplet, because the system is characterized by a low feed solution concentration, typically 0.1% w/v (142). Hence, the resulting particles have a very low particle density of typically less than 0.1 g/cm3.
The experimental evidence in the literature points to DPPC as the primary shell forming excipient in this system. ESCA showed that the surface of particles consisting of albumin, DPPC and a saccharide was enriched in DPPC (147). Surface enrichment was reduced and particle density increased when the co-solvent ratio was shifted to higher ethanol content. This increased the solubility of DPPC which may have led to a decrease in initial DPPC saturation, delaying shell formation according to Eq. 10a, b. DPPC was capable of forming low density particles without the presence of albumin (86,147–149). Removing DPPC from the formulation system led to denser particles (149).
It was shown, however, that the amount of albumin in the formulation also has an effect on the morphology and density of the particles (142,149). Albumin can change particle morphology and lower particle density (107,122,138,150,151) and it can be expected that it has the potential to act as a shell former on its own (85,132,152). Its low diffusion coefficient leads to large Peclet numbers at typical drying gas temperatures. Which shell former dominates the particle formation process depends on their characteristic times to reach a critical surface concentration and their interactions. Particle engineering using this formulation system relies on a proper selection of formulation and process variables, which affect the interaction and particle formation mechanisms of albumin and DPPC.
Large Porous Particles based on the DPPC–albumin formulation system have demonstrated excellent performance in DPI applications for pulmonary drug delivery. Emitted doses in the range of 90–100% from a passive dry powder inhaler were reported (149,153–155). Total lung deposition and dose variability were clearly superior compared to conventional DPI systems (154). It was hypothesized that DPPC may have membrane permeation enhancer properties, leading to increased bioavailability for peptides (153). These particles may further have the potential for sustained release in the lung (143,145,146) due to the low aqueous solubility of the DPPC or avoidance of macrophage uptake (156). A variant of this formulation system, known as Lipid–Protein–Sugar Particles, typically produces smaller particles by spray drying DPPC, albumin, and lactose from an ethanol–water co-solvent system. The primary role of the shell formers in this case is not the reduction of density, but the encapsulation of the active pharmaceutical ingredient. These particles have been suggested for sustained release applications of injectable therapeutics and anesthetics in various tissue targets (157–163).
Large Porous Particles are a part of the AIR® pulmonary drug delivery system (164–166) and have entered late stage clinical trials for insulin (167–169) and early human studies for parathyroid hormone (155,170). They have been used to formulate human growth hormone (153), heparin (171), and small molecules such as albuterol sulfate (144), para-aminosalicylic acid (148), or levodopa (172).
Solid Foam Particles
A comprehensive theoretical description of the formation process for this type of particle has not been published. Spray drying of emulsions has been an intensive area of research in food science, specifically regarding the drying of dairy products. However, a consensus about the mechanisms of emulsion dehydration has not been reached (176). The problem is complex, because several competing sub-processes with similar time-scales need to be considered. The motion of the emulsion nanodroplets causes convective flow in the droplet, the problem cannot be treated as one-dimensional, and momentum conservation cannot be neglected. Still, the lack of diffusional mobility of the dispersed phase may play a role in the particle formation. It has been reported (175,177) that increasing concentration of the dispersed phase leads to the formation of a central internal void of increasing volume, which is consistent with the diffusion controlled particle formation mechanism described above.
In the case of PulmoSpheres™ the dispersed phase typically consists of perfluorooctylbromide (PFOB) (178,179) stabilized with distearoylphophatidylcholine (179–181) or a similar phospholipid (175). The properties of the phospholipid can be optimized using calcium chloride (179,181,182). The active pharmaceutical ingredient is typically dissolved in the continuous phase if it has sufficient aqueous solubility. The continuous phase may also contain additional excipients such as hydroxyethylstarch (183).
Alternatively, poorly soluble molecules may be incorporated into the PulmoSpheres™ particles as smaller separate crystalline particles. In the suspension-based PulmoSpheres™ manufacturing process (181,184), the active is dispersed in the form of micro- or nanocrystals in the continuous phase of the emulsion. This complex suspension is then spray dried and particles are formed that either have the character of carrier particles (180), if the crystals are small enough to be embedded in the typical solid foam structure of the PulmoSpheres™, or are composite particles (184). In the latter case the phospholipid has been shown to form a coat on the dispersed material which provides improved dispersibility. Lipid coating of micronized material can alternatively be achieved by spray drying from a lipid solution in which the microcrystals are suspended (185).
PulmoSpheres™ were originally developed as ultrasound contrast medium (186) and have been administered to the lung by liquid instillation (187–189). They have been applied to pulmonary delivery of several small molecules and peptides (178–180) and have been suggested for vaccination purposes (183,190,191), modulation of immune responses (192) or immunoglobulin delivery (193). The performance of these advanced particles in dry powder inhalers (178,180) or metered dose inhalers (179,194,195) has been shown to significantly exceed that of conventional dosage forms. In a study on pulmonary delivery of tobramycin, the authors found that the delivery of the active using PulmoSpheres™ was nine times as efficient as delivery by a nebulizer (178). A study on budesonide reported a two-fold efficiency advantage relative to a conventional powder formulation (180).
The PFOB used in the manufacturing process of PulmoSpheres™ is often called a blowing agent, which is somewhat misleading, because its boiling point is higher than that of water. Hence, the role of this pore forming agent during the formation process is more that of a placeholder. The use of propellants with much higher vapor pressure than water as the dispersed phase in a formulation system otherwise similar to that of PulmoSpheres™ has been attempted (196). The resulting particles also have very low particle density but posses a morphology that is not foam-like. The formation mechanism for these particles has not been described in detail.
A related approach is the use of volatile salts as pore forming agents to create voids (197,198). Typical examples, termed pore forming agents in the associated literature, are ammonium carbonate (199) or ammonium bicarbonate (200). The volatile salt can be added in various ways to the droplets, as micronized solid in an organic solvent (199,201), dissolved in water (202), or via the dispersed phase of a water-in-oil emulsion (203). Typically, the continuous phase or the organic solvent evaporates first, forming the initial particle morphology which incorporates the solid salt. The volatile salt is then sublimed, typically in a secondary drying or freeze drying step. If the formulation system is compatible with high drying gas temperatures, ammonium bicarbonate may also be removed directly during the spray drying process, as it sublimes at temperatures above 50°C (202).
Particles based on this formulation approach have been developed by Acusphere, Inc. as ultrasound contrast agents (203) and delivery vehicle for poorly soluble drugs (204). In this embodiment the continuous phase consists of a polymer, poly-lactide-co-glycolide or polyvinylpyrrolidone (200), and optionally a lipid, such as diarachidoyl-glycero-phosphocholine, dissolved in suitable solvents such as methylene chloride or ethanol (200). The continuous phase may also contain the active pharmaceutical ingredient. The dispersed phase is an aqueous ammonium bicarbonate solution.
The term microencapsulation has been used in various ways by researchers and developers in food and pharmaceutical sciences. It often simply means that a substance is incorporated into a microparticle and no further description of the particle structure and its effect on the performance of the product is attempted. While in the food industry microencapsulation is often associated with retention of flavor or aroma substances during drying and storage (205–207), pharmaceutical applications usually apply microencapsulation to control the release, improve bioavailability, e.g. through mucoadhesion (208–211), or to mask the taste of an active pharmaceutical ingredient (212,213). The term microencapsulation implies that particles have an outer layer that contains or protects the interior, but this is only one among several particle morphologies that have been reported. Encapsulation in a wider sense can also be accomplished with a homogeneous particle where the matrix itself delays dissolution and release, or with composite particles, where smaller embedded particles or capsules may be covered by additional layers with a barrier function (114,214–216).
Modulating the release of volatile or soluble components from a microparticle in the presence of an external driving force is a difficult task. The release rate from a microparticle is influenced by complex interactions between body fluids, the encapsulant, and the encapsulated material (217). Dissolution, erosion and diffusion of material in the particle not only depend on material properties such as solubility and diffusion coefficients, but also on the morphology of the particle. The rate of diffusion through a layer of encapsulant, for example, depends on its thickness and surface area. In the case of microparticles the layer thickness tends to be variable and on the order of 1 μm or less, and the specific surface area is very large, in particular if pores are present. The small length scales associated with microparticles favor rapid release or an unacceptable burst effect unless the associated diffusion coefficients and solubilities are very low. Hence, materials investigated for microencapsulation of spray dried particles are typically high molecular weight, slowly biodegradable polymers such as polylactide (89,114,118,214,218–224), polylactide-co-glycolide, polycaprolactone (219,225–228), carbomers (229), and methacrylate copolymers (213,230–237), or polysaccharides (238) such as chitosan (215,216,229,239–257), cellulose derivatives (132,213,215,216,229,237,243,245,258), and hyaluronan (238,259), or cross-linked proteins (260). Polylactide-co-glycolide, PLGA, has been studied most intensively and has been used to encapsulate small molecule (94,117,220,224,261–273) and protein (58,219,274–280) therapeutics and various antigens (218,223,227,281–287) for vaccination purposes.
Detailed reviews of different microencapsulation strategies for the purpose of controlled release and adjuvanticity in therapy and vaccination are available (33,249,288–295). This review focuses on a different application of microencapsulation; the use of shells or coats to improve the dispersibility of powders for pulmonary delivery. One approach in particular has attracted significant attention, the use of leucine and trileucine as dispersibility enhancers.
Leucine and Trileucine Particles
Dispersibility is a powder property that still lacks a commonly accepted definition or measure. It is used to describe the degree of dispersion of a powder into individual particles or agglomerates upon exertion of an external dispersion force, e.g. an aerodynamic shear force, typically in a pulmonary delivery device such as a dry powder inhaler. The degree of powder dispersion is important, because it has significant impact on the respirable dose administered to the patient. Many particle parameters affect powder dispersibility; frequently mentioned are size distribution, density, morphology, surface energy, surface roughness, and surface hydrophobicity.
The traditional approach to improving the dispersibility of cohesive powders is to blend them with carrier particles or additives that modify the interparticle forces. Amino acids, lecithin, chitosan and magnesium stearate have been suggested for this purpose (115,296). Among the amino acids, leucine stands out as particularly effective in improving flowability and dispersibility of powder blends (297,298). Therefore, it appears promising to incorporate dispersibility enhancers such as amino acids (115,299,300), specifically leucine, into the particles of a homogeneous powder to encapsulate cohesive material or improve the surface properties of the particles.
The formation mechanism for leucine particles can be derived from the published literature. Pure spray dried leucine forms hollow particles of low density (301,302), demonstrating that leucine is capable of forming a shell, i.e. it has the potential to encapsulate if the particles are designed correctly. Leucine is a weak surfactant (303) with a low molecular weight of 131.17 g/mol. The initial Peclet number for typical drying conditions is small, because its diffusion coefficient in water or ethanol is large. However, the solubility of leucine in water is low, 22 mg/ml, and even lower in ethanol. Consequently, if the initial saturation is sufficient, leucine is expected to reach supersaturation early in the drying process. Leucine may then crystallize, following the particle formation mechanism described above in the section about changing Peclet numbers.
The discussion above shows that encapsulation by leucine relies on a high initial saturation. This can be achieved in several ways that all have their specific disadvantages. A high concentration of the feed solution provides high initial saturation, but also increases the dry particle size, which is undesirable for pulmonary administration. A large fraction of leucine in the formulation can accomplish high initial saturation at lower feed solution concentrations, but is unfavorable for therapeutics that require a large dose, because it leads to a high powder mass and a large excipient load relative to the active. Spray drying from an ethanol water co-solvent system increases the complexity of the processing equipment and may not be compatible with all active pharmaceutical ingredients or other required excipients. An alternative approach is the use of a shell forming excipient that combines many properties of leucine with a lower aqueous solubility. This insight has lead to an investigation of di- and tripeptides as dispersibility enhancers and trileucine has emerged as particularly useful.
The morphology of raffinose, cromolyn, gentamicin, and netilmicin particles was changed to a rugose, low density type with the addition of only 15% trileucine (136,313). A key difference between leucine and trileucine particles is that spray drying of trileucine results in non-crystalline powders, indicating that trileucine precipitates into an amorphous or partially ordered phase (314). This gives trileucine the ability to participate in the stabilization of the active pharmaceutical ingredient, as has been demonstrated with human growth hormone (315). The role of particle engineering in stabilization of particulate dosage forms is discussed in more detail in the next section.
Every pharmaceutical product must remain efficacious and safe during its shelf life. For microparticle products this requirement tends to be complex, because not only the active and the excipients need to remain chemically stable, but also the physical stability of the dosage form must be accomplished. Microparticles produced by spray drying are often in an energetically unfavorable state, because of their large surface area. Also, they frequently have not reached an equilibrium state, because of the short characteristic times of the drying process. Given sufficient mobility, microparticles tend to convert to an energetically more favorable state, either by crystallization (316–320), polymorph transition (321), crystal growth, or fusion of particles (322). All of these processes usually lead to product failure. Chemical stability can be lost through many routes depending on the nature of the active. Some adverse influences like light exposure or moisture and oxygen induced reactions can be mitigated through external protection, e.g. desiccants or oxygen scavengers. However, it is usually preferable to plan for chemical stability during particle design. For degradation that is driven by air–liquid interface exposure, aggregation, or unfolding of proteins there is no other viable option. For biotechnology application particle design also may need to consider biological stability of live organisms. The reader is referred to recent reviews for an introduction into the various stabilization approaches that have been developed (323) and the underlying concepts of physical forms of dry dosage forms (41,314), specifically the nature of amorphous solids (324–326). This review focuses on the particular issues arising in stabilization of spray dried microparticles.
Physical stability of microparticles can be accomplished by designing either a fully crystalline or an amorphous particle with high viscosity (327). Viscosity in an amorphous glass is characterized by the glass transition temperature. Amorphous glasses possess high viscosity if kept well below the glass transition temperature, which is typically designed to be 40 to 50°C above the storage temperature. This strategy, known as glass stabilization, has also been used to provide chemical stability for the active pharmaceutical ingredient, in particular for biologicals. Excipients used for glass stabilization are usually saccharides, polyols, or organic salts that form glasses of high viscosity. Embedding molecules in a rigid amorphous matrix slows degradation reactions by hindering translational motion, but it may not be sufficient to slow fast local rotational and vibrational motions of the molecules. A water replacement strategy may be necessary to achieve stability (106,328). This strategy uses excipients capable of replacing the hydrogen bonds that were broken due to desiccation, or capable of slowing down fast dynamics in glasses. In case of cell or virus formulations, the situation is further complicated by the fact that the inside of the organism can only be protected if stabilizers are transported across its membrane and the difference between interior and exterior environment does not cause damage to the integrity of the cell or virus. Amino acid (35) and saccharide excipients such as glucose (329), sorbitol (106), lactose (330), sucrose (331–337), or trehalose (106,125,182,282,283,332,334,337,338) have been found to be particularly effective in desiccoprotection and have been used in spray drying applications.
When designing stable microparticles manufactured by spray drying, one must consider several challenges that are specific to the microparticle formation process: As discussed above, components in a microparticle tend to separate due to their different diffusional velocities if their Peclet numbers are sufficiently different. It is clearly disadvantageous if stabilizers separate from the molecule they are supposed to stabilize. This mechanism has mostly been neglected in discussions about glass stabilization of microparticles. Rapid droplet evaporation tends to produce dry particles where the composition is a function of the radius. Hence, the glass transition temperature is also expected to be different for the core and the shell of a layered particle (84).
A second mechanism that can lead to unfavorable separation of components is surface activity. A surfactant that is successful in keeping air–liquid interface sensitive molecules away from the surface may unintentionally produce a coat with a low glass transition temperature on the surface that causes unacceptably high cohesive forces between the particles. Alternatively, a surface active protein may at least partially be enriched on the surface, leading to different stabilizer-protein ratios on the surface versus the core of the particle (131).
A third separation mechanism is the sequential precipitation of components due to their different characteristic times to saturation. The situation is further complicated by the fact that the precipitation window for typical spray drying applications is on the order of the characteristic times for crystal nucleation, crystal growth, or polymorph transitions.
A good example for this effect is the variety of physical forms of mannitol that have been observed in spray dried microparticles. Whether mannitol crystallizes during spray drying or subsequently on storage depends on several factors. In a salmon calcitonin–mannitol system the mannitol remained amorphous when the formulation contained less than 50% mannitol, but crystallized when more mannitol was added (321). Similar observations were made during the development of a spray dried monoclonal antibody. Mannitol crystallinity depended on formulation composition (182) and crystallization on stability could be retarded by adding an inhibitor (339). An insulin–mannitol formulation produced crystalline mannitol, whereas an otherwise similar RNAse-mannitol formulation produced amorphous mannitol (340). The sensitivity of the mannitol crystallinity to composition and processing conditions can be explained by similar characteristic times for crystallization and droplet evaporation in typical pharmaceutical applications. This hypothesis is supported by the observation that different polymorphs and an amorphous mannitol fraction were simultaneously present in a salmon calcitonin–mannitol formulation at high mannitol fractions (321,341). According to the Ostwald step rule, crystallization is initiated by forming the least stable polymorph with subsequent transitions to the most stable form. However, if the process cannot proceed to equilibrium, because the loss of mobility occurs faster than the transition to the most stable form, the resulting solid state of the powder is a mixture of non-equilibrium states, which were arrested depending on the length of the precipitation window.
Partially crystalline systems or presence of more than one polymorph has also been observed for other spray dried substances like glycine (342), sucrose (34), polyethylene glycol and lactose (343,344), cromolyn sodium (345), or acetazolamide (346). Particles may also have separated amorphous phases (347), a possible explanation for the destabilizing effect of sucrose at high sucrose to protein ratios. Partially crystalline systems in particular are undesirable for two reasons. Firstly, since the more stable solid form has already been nucleated, the tendency to convert the remaining less stable fraction during storage is increased. This may lead to inferior stability. Once the amorphous fraction starts to crystallize, the water contained in it is mostly expelled and increases the mobility in the remaining amorphous fraction through plasticization. This accelerates the crystallization (348), which usually causes rapid failure. Secondly, a solid dosage form whose physical state is sensitive to small changes in the timing of the drying process is hard to commercialize. Scale-up becomes very difficult, because the longer residence time typical for larger dryers is likely to alter the physical state and, thus the stability of the product (34).
Glass stabilization was introduced to spray dried microparticles by Nektar Therapeutics, San Carlos, CA, and became known under the trademark PulmoSol™ (8,22). The most prominent product in this category is Exubera® (350–352), the first inhalable insulin for the management of diabetes. The spray dried powder used in Exubera® consists of insulin in a buffered formulation of stabilizers. It contains 60% recombinant human insulin, sodium citrate, glycine and mannitol (12,353). The fully amorphous (354) particles have a glass transition temperature of approximately 115°C when completely dry, and of 78–95°C when the moisture content is within storage specifications (351). Physical and chemical stability is excellent, providing 2 years of shelf life at room temperature (355). Comparing the molecular weights of the excipients shows that insulin has the highest Peclet number in this formulation. Considering its high initial concentration in the formulation, the theory presented in this review predicts that insulin is the main shell former and the particles will likely have the typical wrinkled or dimpled protein morphology. Indeed, the Exubera powder morphology shows external voids on particles with a folded shell (351, 356) and is nearly identical to that of pure spray dried insulin (112). These particles have been thoroughly tested in various human trials during the development of Exubera®. Pharmacology, efficacy and safety of the product have been reviewed extensively (9,27,355,357,358).
The examples given in this review show the level of sophistication that can be achieved with a seemingly simple process such as spray drying. Even spray drying from a homogeneous solution, if properly understood, can be used to design particles that have a multifunctional internal structure. Potential further advances in particle engineering may be achieved by combining spray drying with additional processing steps before, during, or after the drying step.
The most common modification to a simple solution spray drying process is the preparation of a suspension or colloid prior to spray drying. Two-phase systems are often necessary because of solubility limitations of active and excipients, but they are also employed to transfer some of the structural properties of the two-phase system onto the final dry particles. A typical example is spray drying from an o/w emulsion to manufacture PulmoSpheres™, where the droplet size of the dispersed phase influences the void size in the dried particles. Ordinary emulsions, mostly o/w emulsions (46–48), and immiscible aqueous (359) and non-aqueous (360) two-phase systems have been studied. Multiple emulsions have also been successfully spray dried, e.g. an O/W/O/W triple emulsion for the encapsulation of orange oil (361). Spray drying of sols (362–365) or suspended solids is a variation of this theme.
Again, the use of a solid dispersion is often dictated by poor solubility and the dispersed solid may simply be micronized or unprocessed material (366–371). Increasingly, though, the dispersed phase has been produced in yet another processing step and possesses specific properties that translate to the final dried particle. Dispersions of small unilamellar liposomes have been spray dried to produce highly dispersible powders for possible pulmonary delivery of superoxide dismutase (372). Spray dried suspensions of dextran microspheres (373) were investigated in the context of nasal drug delivery, pre-formed microcapsules were spray dried to encapsulate phase change materials (374), and dispersions of porous and non-porous silica micro and nanoparticles were spray dried in combination with indomethacin (375), tolbutamide (376), and simvastatin (377). DNA in combination with lyoprotectants was lyophilized, micronized, and subsequently spray dried as a solid-in-oil dispersion to achieve encapsulation in PLGA (378).
A very exciting development is the design of composite particles spray dried from dispersed nanoparticles (51,52,70,73,86,119,365,379–384) or even mixtures of different nanoparticles (385). The nanoparticles are typically manufactured separately prior to preparation of the dispersion and retain their special properties such as enhanced solubility or targeting capacity for the final product. Some of their disadvantages, e.g. their tendency to agglomerate or their unfavorable aerosol transport properties, are mitigated by the fact that they are now part of a larger microparticle (382). It is interesting that the properties of the product are now determined by the primary morphology of the composite particle, the morphology of its nanoscale substructure, and their interactions. This highlights the importance of proper particle design in these systems.
Rather complex dispersion systems with more than one solid dispersed phase have been studied. Calcium salts were dispersed in an aqueous polymeric suspension and then spray dried to produce microencapsulated particles (386). A second example with multiple pre-processing steps is based on a complex dispersion of polymer nanoparticles and micronized fumed silica that was spray dried to produce nanoparticle-coated microparticles (387–393). In this system the drug may be associated either with the organic nanoparticle phase or the inorganic silicon dioxide phase. Several complex dispersions based on o/w emulsions with additional suspended solid material have also been tried. The solid dispersed phase consisted either of the micronized active (181,184), precipitated ethylcellulose (216), or highly porous magnesium aluminometasilicate particles (394).
In the second class of modified spray drying additional steps are added during atomization or drying. Typical examples are atomizer nozzles that allow the mixing of fluids immediately prior to or simultaneous with the atomization process (395,396), or multi-zonal drying chambers, where the droplet evaporation is followed by a secondary drying or firing step that can change the solid state of the particles (397) or remove placeholder material to create porosity (382,398,399). Sophisticated processes, in which spray drying from complex dispersions is coupled with a multi-zonal dryer with three different temperature zones have been presented (400).
Lastly, post-processing steps can be added after spray drying. While secondary drying is common to adjust the moisture content of powder, more intricate processes such as microencapsulation (401) have also been proposed. Developments in the area of bioactive surface layers seem particularly promising. For example, the surface of spray dried microparticles has been loaded with covalently bonded antibodies (402) or adsorbed DNA (403,404) for immunomodulation purposes.
A thorough review of the large number of combination processes where spray dried microparticles play a role is beyond the scope of this review. It will be interesting to follow whether the added functionality of the particles fabricated with such processes will justify their increased complexity in a commercial setting. It is already obvious that the new class of engineered spray dried particles requires a shift in the thinking and structure of pharmaceutical organizations developing them. Because both process and formulation now equally determine key product parameters, it should be reconsidered whether separate groups working on formulation and process development, optimization and scale-up are adequate. This new class of products demands a unified design approach reflected in an organizational structure that allows constant collaboration of formulators and process engineers in a single group. It also becomes evident that purely empirical approaches to product design are doomed to fail in a situation where the parameter space is defined by a very large number of formulation and process variables. Successful design of engineered particles requires thorough understanding and predictive modeling, so that the early development process can be completed in an acceptable time with a high likelihood of success. Much of the fundamental work, including the measurement of urgently needed material properties remains to be done.